All In MedTech

FDA Clearance Tracker · P170011-S025

Impella RP System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 4, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 4, 2020

Approved

Time to decision

50 days

Received Jun 15, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P170011-S025
Device name
Impella RP System
Applicant
Abiomed, Inc.
Applicant location
Danvers, MA
Received
Jun 15, 2020
Decided
Aug 4, 2020
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P170011

Device type

Device class
Class III
Regulation
21 CFR 870.4360
Specialty
Cardiology

Every decision under product code PYX

FDA's approval statement

As written in FDA's record.

Approval for a labeling change related to the Impella RP best practice selection algorithm.

Source documents

Other decisions for Abiomed, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.